CAR T-Cell Therapy

FDA grants designations to off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

Phase 1 TRAVERSE results show that off-the-shelf CD70 CAR T ALLO-316 drives durable responses in refractory clear cell kidney cancer, with manageable safety signals.

During a live event, Prerna Mewawalla, MD, discussed the choice between bispecific antibody therapy and CAR T-cell therapy in myeloma as both therapies have been introduced earlier in sequence.

During a live event, Syed Abbas Ali, MBBS, and participants discussed treatment selection for a patient who has not yet received BCMA-targeted therapy after a second relapse of multiple myeloma.

Results from the SPEARHEAD-1 trial supported FDA approval of the engineered T-cell product for patients as young as 12 years of age.

During a live event, Prerna Mewawalla, MD, and participants discussed selecting therapy for patients with early relapsed/refractory multiple myeloma who are not candidates for CAR T-cell therapy.

At the EHA 2026 Congress, researchers presented novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

A retrospective analysis shows strong outcomes with CAR T-cell therapy in real-world patients with multiple myeloma, Doris K. Hansen, MD, explains.

During a live event, Sikander Ailawadhi, MD, and participants discussed sequencing and bridging therapy selection for patients with early relapsed multiple myeloma who are candidates for CAR T-cell therapy.

During a live event, Syed Abbas Ali, MBBS, and participants discussed current referral practices for second-line CAR T-cell therapy in multiple myeloma.

In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.

Phase 2 ALPHA3 shows cema-cel in MRD-positive large B-cell lymphoma has no CRS/ICANS so far, enabling outpatient consolidation with manageable adverse effects.

Interim ALPHA3 data show cema-cel clears ctDNA MRD in high-risk DLBCL after frontline therapy, prompting continued study of consolidation CAR T.

Omar Nadeem, MD, discusses results of the CAR-PRISM trial in smoldering myeloma.

A phase 1 trial investigating autologous KMCAR T cells has been initiated in patients with relapsed/refractory multiple myeloma.

CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from receiving it.

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

Community oncology teams partner with health systems to deliver advanced therapies safely, using hybrid dosing, toxicity backup, and local follow-up.

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to expand access.

ZUMA-2 cohort 3 shows brexu-cel CAR T delivers 91% responses in mantle cell lymphoma, with manageable CRS/ICANS, driving full FDA approval.

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose testing and expanded eligibility, enabling full FDA approval.

Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a game-changing option.